Stefan Schwartz

16PUBLICATIONS
96CO-AUTHORS
Gene and molecular therapyHaematological tumoursEpidemiological methodsCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Mar 13, 2026
IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Johanna M Horns, Thomas Beder, Axel Künstner

|Jan 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Oct 20, 2025
Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.

M Korenkov, J Liebaert, S Yousefian

|Jul 25, 2025
Retraction Note: New recommendations for reversal of high-dose methotrexate cytotoxicity with folinic acid.

Jesper Heldrup, Archie Bleyer, Laura Ramsey

|May 21, 2025
Reply to: Methotrexate toxicity and glucarpidase: A call for dose optimization. Koppen A, et al. Br J Clin Pharmacol. 2025;91(5):1289-1292 doi:10.1002/bcp.70044.

Carmelo Rizzari, Stefan Schwartz

Pageof 3

Frequent Collaborators

4 joint publications

Etienne Chatelut

4 joint publications

Carmelo Rizzari

4 joint publications

Scott Howard

4 joint publications

Miriam Hwang